

Op 2161

Patent  
256/301



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Glen J. Anderson

Serial No.: 09/751,890

Filed: December 27, 1000

For: A Method and System for Providing and  
Updating Customized Health Care Information  
Based on an Individual's Genome

Group Art Unit: 2161

Examiner: Not yet assigned

INFORMATION DISCLOSURE STATEMENT

Box Non-Fee  
Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
APR 30 2001  
Technology Center 2100

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

☒ This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

April 23, 2001  
Date of Deposit

Sally Hartwell

Name of Person Mailing Paper

Signature of Person Mailing Paper-0

filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

- ☒ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.
- ☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.
- ☐ This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.
- ☐ The fee due under 37 CFR § 1.17(p) is submitted herewith.
- ☐ A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.
- ☐ This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

**STATEMENT UNDER 37 CFR § 1.97(e):**

- ☐ Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- ☐ No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**


☐ A check in the amount of \_\_\_\_\_ is enclosed for the above fee(s).

☐ Please charge \_\_\_\_\_ to Gateway's Deposit Account No. **50-0439** for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **50-0439**.

Respectfully submitted,  
LYON & LYON LLP

Dated: 04/23/2001

By:   
Ivan Posey  
Reg. No. 43,865

Enclosures: 14 Prior Art References



**22249**

LYON & LYON LLP  
633 W. Fifth Street,  
Suite 4700  
Los Angeles, CA  
90071

256/301

09/751,890

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

## APPLICANT:

Glen J. Anderson

## FILING DATE:

December 27, 1000

## GROUP:

2161

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	1.	5,590,648	1/7/1997	Mitchell, et al.			
	2.	5,722,418	3/3/1998	Bro			
	3.	5,732,709	3/31/1998	Tackline, et al.			
	4.	5,748,907	5/5/1998	Crane			
	5.	5,911,687	6/15/1999	Sato, et al.			
	6.	5,995,937	11/30/1999	DeBusk			
	7.	6,014,631	1/11/2000	Teagarden, et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	AI						
	AJ						
	AK						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

8.	Copyright 2000 Responsive Database Services, Inc., Business and Industry, "DNA Detectives", pp. 1-10, <a href="http://web.lexis-nexis.com/In.universe">http://web.lexis-nexis.com/In.universe</a>
9.	Copyright 2000 Mainichi Daily News, "Gene counseling sadly lags behind Technology", pp. 1-2, May 26, 2000, <a href="http://web.lexis-nexis.com/In.universe">http://web.lexis-nexis.com/In.universe</a>
10.	CNN.com Health, "Your Health: Implications of the Human Genome Project", <a href="http://www.cnn.com">http://www.cnn.com</a> , March 17, 2000
11.	CNN.com Health, Jeffrey P. Khan, "Who owns your genes?", March 21, 2000, <a href="http://www.cnn.com/2000/Health/03/21/ethics.matters">http://www.cnn.com/2000/Health/03/21/ethics.matters</a>
12.	CNN.com technology > computing, "Have your genes sequenced online", May 24, 2000, <a href="http://www.cnn.com/2000/T...05/24/dot.coms.and.genes.idg/index.html">http://www.cnn.com/2000/T...05/24/dot.coms.and.genes.idg/index.html</a>
13.	CNN.com Health, "Milestone in human genetics to be announced Monday", June 23, 2000, <a href="http://www.cnn.com/2000/HEALTH/06/23/genome/index.html">http://www.cnn.com/2000/HEALTH/06/23/genome/index.html</a>
14.	DoubleTwist, "Twist Tools and DoubleTwist Human Genome Database", <a href="http://www.DoubleTwist.com">http://www.DoubleTwist.com</a>

## EXAMINER:

Not yet assigned

## DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant